Moderna RSV Shot 50 Percent Effective After 18 Months

(Dreamstime)

Wednesday, 26 June 2024 09:51 AM EDT ET

Moderna Inc respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months, the drugmaker said on Wednesday.

In their clinical trials, GSK's RSV vaccine Arexvy was 78% effective in preventing severe RSV over a second year and Pfizer's was 78% effective midway through a second RSV season.

Moderna presented the data at a meeting of the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices. The drugmaker has previously cautioned against comparing its vaccine to rivals, noting that the trials were not head-to-head and used different case definitions for RSV disease. 

© 2024 Thomson/Reuters. All rights reserved.


Health-News
Moderna Inc respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months, the drugmaker said on Wednesday. In their clinical trials, GSK's RSV vaccine Arexvy was 78% effective in preventing severe RSV over a second year and Pfizer's...
rsv, vaccine, moderna, mresvia
99
2024-51-26
Wednesday, 26 June 2024 09:51 AM
Newsmax Media, Inc.

View on Newsmax